BioRestorative Therapies Inc 公布其与美国食品药品监督管理局(FDA)举行的B类会议结果积极。
该公司目前预期将于2026年下半年提交三期临床试验的新药研究申请。
BioRestorative Therapies Inc 公布其与美国食品药品监督管理局(FDA)举行的B类会议结果积极。
该公司目前预期将于2026年下半年提交三期临床试验的新药研究申请。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.